Summary

Eligibility
for people ages up to 45 years (full criteria)
Location
at UCSF
Dates
study started
study ends around

Description

Summary

The objective of the International Rare Brain Tumor Registry (IRBTR) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed with rare brain tumors.

Details

The International Rare Brain Tumor Registry (IRBTR) is a prospective observational study that will collect tumor samples and matched clinical and radiological data to better understand the outcomes of patients with rare brain tumors in particular: CNS sarcoma, BCOR, MN-1 altered tumors, PLAG/L1, and other rare or unclassified rare brain tumors.

Data collected include demographics, disease characteristics, treatment information, radiological imaging, and biospecimen collection if available ( tumor tissues Patients will be followed longitudinally to obtain outcome data. Data collection will continue for approximately 10 years.

Keywords

Astroblastoma, BCOR ITD Sarcoma, CNS Sarcoma, Unclassified Tumor, Malignant, Rare Brain Tumor, Pediatric Brain Tumor Registry, Unclassifiable tumor, Pediatric Neuro-Oncology, Rare Disease, Neuroepithelial Neoplasms, Neoplasms, Rare Diseases, BCOR-altered, Astroblastoma/MN-1- altered, Unclassifiable tumors, Other Rare Brain tumors

Eligibility

You can join if…

Open to people ages up to 45 years

  • Patients with a known or suspected CNS Sarcoma.
  • Patients with a known or suspected BCOR-altered brain tumor
  • Patients with a known or suspected Astroblastoma/NM-1 altered brain tumor
  • Patients with known or suspected histologically ambiguous/unclassifiable brain tumor
  • Patients with a known or suspected rare brain tumor.
  • Signed informed consent by patient/ parent or guardian (assent where applicable) to participate in the study.

You CAN'T join if...

  • The patient has an extra-CNS primary tumor.
  • The patient is older than 46 years of age at diagnosis.
  • The patient or family is not willing to participate or does not sign informed consent.

Locations

  • Marie Jaeger-Krause accepting new patients
    San Francisco 5391959 California 5332921 94158 United States
  • Nathan Robison accepting new patients
    Los Angeles 5368361 California 5332921 90027 United States
  • Scott Raskin accepting new patients
    Cincinnati 4508722 Ohio 5165418 45229-3026 United States
  • Children's National Hospital accepting new patients
    Washington D.C. 4140963 District of Columbia 4138106 20010 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Children's National Research Institute
ID
NCT05697874
Study Type
Observational [Patient Registry]
Participants
Expecting 5800 study participants
Last Updated